CMV DNA is rarely detected in healthy blood donors using validated PCR assays

被引:60
作者
Roback, JD
Drew, WL
Laycock, ME
Todd, D
Hillyer, CD
Busch, MP
机构
[1] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA
[2] Univ Calif San Francisco, Sch Med, Dept Lab Med, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA
[4] Blood Ctr Pacific, Res Sci Serv, San Francisco, CA USA
[5] Westat Corp, Rockville, MD USA
关键词
D O I
10.1046/j.1537-2995.2003.00312.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Although serologic screening or WBC reduction of blood components can reduce the incidence of transfusion-transmitted CMV (TT-CMV) infection, 'breakthrough' cases of TT-CMV still occur and may produce serious sequelae. NAT of blood components for CMV DNA has been proposed to further reduce the risks of TT-CMV. However, large-scale studies to determine the utility of validated CMV NAT assays for donor screening have not been reported. STUDY DESIGN AND METHODS: Coded whole-blood samples (n = 1000) were tested for the presence of CMV DNA using two CMV PCR assays previously validated in a multicenter trial (a nested PCR assay directed at the CMV UL93 open-reading frame and the Roche Monitor assay). Corresponding plasma samples were tested in parallel for the presence of anti-CMV using other assays (Abbott CMV EIA and Fujirebio/Olympus CMV particle agglutination assays). RESULTS: In total 416 and 514 of the samples tested as CMV-seropositive and -seronegative, respectively, by both antibody assays. The remaining 70 samples had discrepant serology results. Only 2 of the 1000 samples (both seropositive) had reproducibly detectable CMV DNA (positive in at least three of four replicates). CMV DNA was not reproducibly detected in seronegative samples or in samples with discrepant serology results. CONCLUSIONS: Although previous investigations showed frequent detection of CMV DNA in healthy CMV-seropositive (and some seronegative) blood donors, these studies were relatively small and the performance characteristics of their assays were difficult to evaluate. In contrast, the present large cross-sectional study of US donors utilized two previously validated PCR assays and demonstrated that CMV DNA is only rarely detectable in seropositive donors. Thus, the use of CMV PCR assays with optimal performance characteristics did not increase the detection of potentially infectious blood components beyond that provided by current serologic screening assays.
引用
收藏
页码:314 / 321
页数:8
相关论文
共 43 条
[1]   POLYMERASE CHAIN-REACTION FOR DETECTION OF HUMAN CYTOMEGALOVIRUS-INFECTION IN A BLOOD-DONOR POPULATION [J].
BEVAN, IS ;
DAW, RA ;
DAY, PJR ;
ALA, FA ;
WALKER, MR .
BRITISH JOURNAL OF HAEMATOLOGY, 1991, 78 (01) :94-99
[2]   FAILURE TO DETECT HUMAN CYTOMEGALOVIRUS DNA IN PERIPHERAL-BLOOD LEUKOCYTES OF HEALTHY BLOOD-DONORS BY THE POLYMERASE CHAIN-REACTION [J].
BITSCH, A ;
KIRCHNER, H ;
DUPKE, R ;
BEIN, G .
TRANSFUSION, 1992, 32 (07) :612-617
[3]   Peripheral blood CD14+ cells from healthy subjects carry a circular conformation of latent cytomegalovirus genome [J].
Bolovan-Fritts, CA ;
Mocarski, ES ;
Wiedeman, JA .
BLOOD, 1999, 93 (01) :394-398
[4]   THE RISK OF TRANSMITTING CYTOMEGALOVIRUS-INFECTION BY FRESH-FROZEN PLASMA [J].
BOWDEN, R ;
SAYERS, M .
TRANSFUSION, 1990, 30 (08) :762-763
[5]   CYTOMEGALOVIRUS IMMUNE GLOBULIN AND SERONEGATIVE BLOOD PRODUCTS TO PREVENT PRIMARY CYTOMEGALOVIRUS-INFECTION AFTER MARROW TRANSPLANTATION [J].
BOWDEN, RA ;
SAYERS, M ;
FLOURNOY, N ;
NEWTON, B ;
BANAJI, M ;
THOMAS, ED ;
MEYERS, JD .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (16) :1006-1010
[6]   A COMPARISON OF FILTERED LEUKOCYTE-REDUCED AND CYTOMEGALOVIRUS (CMV) SERONEGATIVE BLOOD PRODUCTS FOR THE PREVENTION OF TRANSFUSION-ASSOCIATED CMV INFECTION AFTER MARROW TRANSPLANT [J].
BOWDEN, RA ;
SLICHTER, SJ ;
SAYERS, M ;
WEISDORF, D ;
CAYS, M ;
SCHOCH, G ;
BANAJI, M ;
HAAKE, R ;
WELK, K ;
FISHER, L ;
MCCULLOUGH, J ;
MILLER, W .
BLOOD, 1995, 86 (09) :3598-3603
[7]  
BOWDEN RA, 1991, BLOOD, V78, P246
[8]   PRIMER-MEDIATED ENZYMATIC AMPLIFICATION OF CYTOMEGALO-VIRUS (CMV) DNA - APPLICATION TO THE EARLY DIAGNOSIS OF CMV INFECTION IN MARROW TRANSPLANT RECIPIENTS [J].
CASSOL, SA ;
POON, MC ;
PAL, R ;
NAYLOR, MJ ;
CULVERJAMES, J ;
BOWEN, TJ ;
RUSSELL, JA ;
KRAWETZ, SA ;
PON, RT ;
HOAR, DI .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (04) :1109-1115
[9]  
DEGRAANHENTZEN YCE, 1989, TRANSFUSION, V29, P757
[10]   PREVENTION OF PRIMARY CYTOMEGALOVIRUS-INFECTION AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION BY USING LEUKOCYTE-POOR RANDOM BLOOD PRODUCTS FROM CYTOMEGALOVIRUS-UNSCREENED BLOOD-BANK DONORS [J].
DEWITTE, T ;
SCHATTENBERG, A ;
VANDIJK, BA ;
GALAMA, J ;
OLTHUIS, H ;
VANDERMEER, JWW ;
KUNST, VAJM .
TRANSPLANTATION, 1990, 50 (06) :964-968